Jiangsu Hengrui Medicine
600276.SS
#467
Rank
S$64.96 B
Marketcap
S$9.79
Share price
-1.18%
Change (1 day)
15.77%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): S$1.54 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are S$4.19 Billion. In 2024 the company made an earning of S$1.26 Billion, an increase over its 2023 earnings that were of S$0.84 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) S$1.54 B21.81%
2024 S$1.26 B50.59%
2023 S$0.84 B11.35%
2022 S$0.75 B-13.82%
2021 S$0.87 B-34.16%
2020 S$1.33 B16.28%
2019 S$1.14 B32.92%
2018 S$0.86 B20.82%
2017 S$0.71 B23.8%
2016 S$0.57 B11.25%
2015 S$0.51 B39.52%
2014 S$0.37 B20.71%
2013 S$0.30 B11.46%
2012 S$0.27 B29.6%
2011 S$0.21 B31.28%
2010 S$0.16 B27.89%
2009 S$0.12 B5.84%
2008 S$0.12 B79.89%
2007 S$66.73 M32.93%
2006 S$50.2 M38.14%
2005 S$36.34 M21.56%
2004 S$29.89 M13.95%
2003 S$26.23 M38.06%
2002 S$19 M